MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.83
+0.06
+0.89%
Closed 16:00 09/25 EDT
OPEN
6.80
PREV CLOSE
6.77
HIGH
7.15
LOW
6.76
VOLUME
311.47K
TURNOVER
--
52 WEEK HIGH
8.05
52 WEEK LOW
1.480
MARKET CAP
263.86M
P/E (TTM)
-3.8948
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Stocks To Watch: All Eyes On Tesla Battery Day
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links). Tesla (TSLA) will take top billing this week with its highly-anticipated Battery Day event having the potential to charge up animal spirits in the market again. The earnings calendar features high-flyers Nike (NKE) and Costco (COST), while Apple (AAPL) will
Seekingalpha · 09/19 12:29
Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., Chief Financial Officer Joshua Reed, and Chief Commercial Officer David McMullin will be participating in a fireside chat and hosting one-on-one meetings at Oppenheimer’s Fall Healthcare
Business Wire · 09/16 13:00
Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences:
Business Wire · 09/10 12:00
Aldeyra on go with mid-stage study of ADX-629 in COVID-19
Aldeyra Therapeutics (ALDX) announces that the FDA has signed off on a 30-subject Phase 2 clinical trial evaluating ADX-629 in hospitalized adult COVID-19 patients.Participants will be enrolled upon hospitalization for
Seekingalpha · 09/09 12:44
Aldeyra Receives Study May Proceed Letter From FDA To Initiate Clinical Trial Of ADX-629 In COVID-19 Patients
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial evaluating
Benzinga · 09/09 12:02
Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial evaluating ADX-629, a novel orally available reactive aldehyde species (RASP) inhibitor, for the treatment
Business Wire · 09/09 12:00
Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D., will participate in an ophthalmology panel discussion during Citi’s 15th Annual BioPharma Virtual Conference, taking place September 8-11, 2020. In addition, Aldeyra
Business Wire · 09/03 12:00
Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?
Is (ALDX) Outperforming Other Medical Stocks This Year?
Zacks · 08/25 16:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALDX. Analyze the recent business situations of Aldeyra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALDX stock price target is 27.71 with a high estimate of 34.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 122
Institutional Holdings: 16.85M
% Owned: 43.61%
Shares Outstanding: 38.63M
TypeInstitutionsShares
Increased
19
1.34M
New
48
1.44M
Decreased
26
4.79M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Senior Vice President
James Gow
Senior Vice President
Stephen Machatha
Other
David McMullin
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Jesse Treu
Independent Director
Neal Walker
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALDX
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.